SANTA ANA, CA--(Marketwired - Nov 18, 2013) - BioLargo, Inc. (
"This newly issued patent covers the product sold to the US Government as well as many of our other award winning products, including our Cat Litter Deodorizing Concentrate that was just named a Cat Fancy 'Best Product of 2013.' Our customers love the products because they work so well and consistently outperform the competition. While our first orders with the US Government have thus far been small, we are now an approved supplier to the system and are developing more knowledge and skill to navigate the procurement process. We are excited about these opportunities to expand sales as we also work to increase our working capital resources," stated BioLargo's president, Dennis Calvert.
About BioLargo, Inc.
We make life better by delivering technology-based products that help solve some of the world's most important problems that threaten our water, food, agriculture, healthcare and energy. Our website is www.BioLargo.com. Our subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, and consumer markets, including the Nature's Best Solution® and Deodorall® brands. (www.OdorNoMore.com). Our subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com), focuses on advanced wound care management and is preparing to make FDA 510(k) applications in early 2014. Our subsidiary BioLargo Water, Inc. (www.BioLargoWater.com), showcases our "advanced oxidation systems," including its AOS filter, a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time of current technologies. BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2012.
Dennis P. Calvert